1-Cyclopentyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Catalog No. :
ACEIHZ234
CAS No. :
2096334-27-7
Molecular Formula :
C14H23BN2O2
Molecular Weight :
262.16

IUPAC Name:1-cyclopentyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

1-Cyclopentyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$61.00Login to see priceIn stockInquiry
5g97%$208.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Cyclopentyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
IUPAC Name1-cyclopentyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
MDL No.MFCD21333042
Molecular FormulaC14H23BN2O2
Molecular Weight262.16
SMILESCC1(C)C(C)(C)OB(C2=CC=NN2C3CCCC3)O1
InChI KeyIDSSRSBZJMSRGW-UHFFFAOYSA-N
Synonym1-Cyclopentyl-1H-pyrazole-5-boronic acid, pinacol ester;1H-Pyrazole, 1-cyclopentyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.2096334-27-7
PubChem CID74789488

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACEIHZ234 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRHKV847 route compound structure diagram
    ACRHKV8471086111-17-2 In Stock
  4. Then
  5. ACEIHZ234 route product structure diagram
    ACEIHZ2342096334-27-7 In Stock
Inquiry

2. ACEIHZ234 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRHKV847 route compound structure diagram
    ACRHKV8471086111-17-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEIHZ234 route product structure diagram
    ACEIHZ2342096334-27-7 In Stock
Inquiry

Comments (0)